Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH-R2: Sintilimab + Hypo-RT in Recurrent Rectal Cancer
NCT06928584Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2025
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in rectal cancer (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 3 years. Started Mar 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06928584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928584.